{
    "organizations": [],
    "uuid": "d310bdf3b198befbf0f325163277e4e75b37437c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-immunomedics-announces-agreement-w/brief-immunomedics-announces-agreement-with-university-of-wisconsin-carbone-cancer-center-to-expand-sacituzumab-govitecan-into-prostate-cancer-idUSFWN1P60KY",
    "ord_in_thread": 0,
    "title": "BRIEF-Immunomedics Announces Agreement With University Of Wisconsin Carbone Cancer Center To Expand Sacituzumab Govitecan Into Prostate Cancer",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 11 (Reuters) - Immunomedics Inc:\n* IMMUNOMEDICS ANNOUNCES AGREEMENT WITH UNIVERSITY OF WISCONSIN CARBONE CANCER CENTER TO EXPAND SACITUZUMAB GOVITECAN (IMMU-132) INTO PROSTATE CANCER\n* IMMUNOMEDICS INC - ‍IMMUNOMEDICS TO FUND PHASE 2 STUDY SPONSORED BY UNIVERSITY OF WISCONSIN​ Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.",
    "published": "2018-01-11T21:18:00.000+02:00",
    "crawled": "2018-01-12T18:45:02.008+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "immunomedics",
        "inc",
        "immunomedics",
        "announces",
        "agreement",
        "university",
        "wisconsin",
        "carbone",
        "cancer",
        "center",
        "expand",
        "sacituzumab",
        "govitecan",
        "prostate",
        "cancer",
        "immunomedics",
        "inc",
        "fund",
        "phase",
        "study",
        "sponsored",
        "university",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}